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Abstract 
To determine the interrater reliability of clinical descriptors for Alzheimer’s disease (AD), we assessed the degree of agree-
ment among four clinicians who rated 21 patients during a longitudinal study. Despite variability in response patterns,
degree of agreement for determining age at onset of dementia was statistically significant (P < 0.005). We also found
significant agreement (P < 0.0001) among three clinicians for the clinical descriptor, "age at shift" from questionable to
probable AD, according to the National Institutes of Health Consensus Criteria. These data demonstrate that both retro-
spective and prospective descriptors can be reliably determined in the clinical assessment of AD. (J Geriatr Psychiatry Neurol
1988;1:207-211).
Although the clinical characterization of Alz-eimer’s disease (AD) is an essential aspect
of current research efforts into etiology and treatment,
few data are available on the reliability of assessment.
Age at onset of dementia has been a widely used mea-
sure since the disease’s first description in 1907 as a
presenile dementia. Throughout the century, how-
ever, there has been controversy regarding the etio-
logical and clinical significance of age at onset. How
accurate are retrospective reports of relatives in deter-
mining age at onset? Are there different subtypes of
the illness according to age at onset? If so, what age
should subdivide these subtypes? Even more funda-
mentally, how should investigators operationally de-
fine age at onset? And, once defined, how consistent
is this clinical measure? Despite considerable research
on early-onset and late-onset AD, the controversy
behind such questions remains unresolved.
In this report, we assess the interrater reliability
of age at onset of Alzheimer-type dementia as well as
a new clinical descriptor that may be useful in longi-
tudinal studies of AD: the &dquo;age at shift&dquo; from ques-
tionable to probable AD, according to the National
Institutes of Health (NIH) Consensus Criteria.2 
2
Subjects and Methods
The study was performed on 21 patients (10 women
and 11 men) from a larger ongoing project investi-
gating positron emission tomography of local cerebral
functions in patients with early-onset AD.3 Diagnosis
was made following psychiatric, neurological, and
neuropsychological examination. Several standard-
ized rating scales used to characterize the degree,
nature, and rate of decline of these patients included
the Mini-Mental State Examination (MMSE),4 the
Blessed-Tomlinson-Roth Dementia Scale (Blessed
Scale),5 the Clinical Dementia Rating Scale (CDR),6 6
the Hamilton Rating Scale for Depression (HRSD),’
and the Ischemic Scale.8
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To determine age at onset, family members, sur-
rogates, or friends were asked when they first noted
any mental or behavioral changes in the patient. This
question was posed to the same informant by each of
the health care professionals performing the initial
patient evaluations, ie, a geriatric psychiatrist, a
neurologist, a psychologist, and a nurse. The earliest
age at onset from these four sources was used for
comparisons with other variables. Age at shift was
defined as the age during the follow-up period when
the patient was first diagnosed as having probable AD.
Probable AD was diagnosed when the following
criteria were satisfied: (1) presence of dementia was
established by clinical examination, documented by
standardized rating scales (eg, Mini-Mental State
Examination), and confirmed by neuropsychological
testing (Wechsler Adult Intelligence Scale-Revised
[prorated version], Benton Visual Retention Test,
Number Cancellation Protocol, Symbol Digit Modali-
ties Test, Ravens Color Progressive Matrices Test,
Hooper Visual Organization Test, Rey Auditory-
Verbal Test, and Trial Making Test [Part A and Part
B]); (2) deficits were present in two or more areas of
cognitive functioning; (3) loss of memory and other
cognitive functions was progressive; (4) level of con-
sciousness was not disturbed; (5) onset was between
ages 40 and 75 years; and (6) no other systemic dis-
order or brain disease could account for the deficits.2 2
Routinely recommended laboratory studies used
to exclude other diseases that could cause dementia
included complete blood count with sedimentation
rate; analysis of urine; determinations of serum cre-
atinine, urea nitrogen, glucose, electrolytes, bilirubin,
vitamin B12, and folic acid levels; serological test for
syphilis; tests for thyroid function (T4, T3, and TSH);
tests for liver function (SGOT, SGPT); electrocar-
diogram ; electroencephalogram; and computerized
tomographic (CT) scan of the head.9 Patients with
multi-infarct dementia were excluded by clinical
examination and a score of 4 or more on the Ischemic
Scale.8 A score of 23 or less on the MMSE4 as well as
4 or more on the Blessed Scale5 was used as docu-
mentation of dementia. All patients scored a 0.5 or
1 on the CDR6 on entry into the study. The MMSE,
Blessed Scale, and CDR were also used to document
progessive cognitive decline, and patients were fol-
lowed at 6- to 12-month intervals, which increased
our confidence in clinical diagnosis. A geriatric psy-
chiatrist (GWS, JWA) and neurologist (DGF) examined
patients at each interval and independently deter-
mined diagnostic categories. Another diagnostic de-
termination was then made by a third clinician (DEK)
following review of the medical record.
To assess the degree of association between age
at onset and age at shift as well as associations
with other clinical and demographic variables, we
calculated Pearson’s product-moment. The Kendall
coefficient of concordance was used to calculate the
degree of agreement for age at onset. Agreement for
age at shift was determined by the Lawlis and Lu
approach. 10
Results
Clinical and demographic characteristics of the pa-
tients are listed in Table 1. Age at onset of the patients
ranged from 45 to 75 years with a mean of 61.32 +
6.90 (SD). Age at shift ranged from 54 to 77 years with
TABLE 1
Characteristics of Patients (Mean ± SD)
* (1) = time of initial examination, (S) = time of shift from questionable to probable AD.
t 
= change in rating scale divided by number of months between first and last examination.
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FIGURE 1 ’
Age at onset-determinations of four clinicians.
a mean of 66.43 ± 5.99. The distribution of age at
onset and age at shift for our sample was not bimodal
but instead approached a normal distribution. Age at
onset correlated highly with age at shift (r = 0.95, P <
0.0001), suggesting that these patients experienced
similar rates of decline since the reported onset of
illness. Age at shift and age at onset did not correlate
with several other variables, including rate of decline,
duration of illness, years of education, and severity of
illness.
Although histories were obtained from the same
informants, there was variability in age at onset, as
determined by the different health care professionals
(Figure 1). There was total agreement for only 3 of the
21 patients. For one patient, the range for age at onset
was 5.5 years. When we looked at response patterns
for individual health care professionals, the average
differences from the mean age at onset were as
follows: nurse, +0.30 years; neurologist, -0.25 years;
psychiatrist, -0.16 years; and psychologist, +0.25
years. Despite this variability, when we ranked the
ages at onset for each rater and calculated the Kendall
coefficient of concordance, agreement was statistically
significant (W = 0.96, x2 = 76.8, df = 20, P < 0.005).
To determine the degree of agreement for age at
shift, we counted the number of total agreements for
diagnosing probable AD after the initial visit (ie, all
three clinicians agreed) for the 17 patients who re-
ceived two or more follow-up examinations; data for
the 4 patients who received only one follow-up ex-
amination each were excluded from this calculation.
Under these circumstances, the probability for total
agreement by chance is 0.11, whereas the calculated
t value is 0.87 (x2 = 96.39, df = 1, P < 0.0001).
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Discussion
Although agreement among clinicians was statistically
significant, we found variability in determination of
age at onset, even when histories were obtained from
the same informants. Response patterns differed
among the various professionals, with the physician
interviewers (geriatric psychiatrist and neurologist)
identifying earlier ages at onset than the nonphysician
interviewers (psychologist and nurse). Educational
and prior professional experience, as well as other
factors, such as personal experience, interview style,
and countertransference, may have influenced these
determinations. Despite this variability in assess-
. ments, there was statistically a high level of concord-
’ 
ance, which may reflect, in part, the relatively wide
range of age at onset (48 to 75 years of age) in this
sample population. When more narrow age ranges
are studied, the level of concordance will be lower.
The use of standardized interview schedules in de-
mentia research could eliminate some of this vari-
ability, though such widely used instruments as the
Diagnostic Interview Schedule or the Standard Clini-
cal Interview for DSM-III have not yet been fully
developed for adequate assessment of cognitive
disorders.ll Even if standardized questions are used,
other sources of variability remain. These include
how well the informant knows the patient, the dis-
tortion introduced by emotionally laden memories of
past events, and variability of the informant’s recall
over time.
Even though informants may agree on age at on-
set, their reports may be inaccurate. Considering that
patients early in the course of AD tend to deny symp-
toms, critical points in clinical characterization may
be unobserved in these early stages. In a study of 16
patients with probable AD, Watson and colleaguesl2
found rough validity to relatives’ recall of dementia
symptoms and their progression over time. They
compared relatives’ ratings of function at initial and
follow-up evaluations with retrospective estimates of
the extent of change over the same time period, and
found that informants tended to report slightly less
change than what had actually taken place. Other
investigators&dquo; found a tendency for relatives to under-
report symptorris of prior psychopathology.
Our data demonstrate the reliability of using age at
shift as a clinical descriptor of AD in prospective
longitudinal studies, although there was diasgree-
ment on some of our cases. The NIH Consensus
Criteria specify the kinds of information (eg, clinical
history, laboratory test results) necessary to diagnose
probable AD, but operational procedures for obtain-
ing such information are not provided, which may
explain some discrepancies. Moreover, the Consensus
Criteria suggest standardized rating scales, but do
not provide cutoff points for these scales. We recom-
mend further delineation of and operational defini-
tions for existing diagnostic criteria to help minimize
disagreement.
In our study, age at onset correlated highly with
age at shift, suggesting that the rate of deterioration
for patients was similar regardless of age. The small
sample size may explain the lack of correlation be-
tween age at onset or age at shift with other variables.
Whether age at shift has greater precision than age
at onset in determining subtypes of AD is a ques-
tion awaiting further study using larger samples. The
problems of basing the determining factor on retro-
spective reports from relatives are eliminated by
using age at shift. Some of the controversy regarding
subtyping AD may thus be resolved.
The accepted convention for subdividing AD has
been to identify two groups, early-onset and late-
onset. Most investigators use a cutoff age of 65 years,
some use the age of 60 years, adding further’~confu-
sion when attempts are made to compare results of
studies using different criteria. 14 Given the small
sample size and uniformity in rate of decline for this
sample, it would be premature to assign such a cutoff
age to separate &dquo;early-shift&dquo; from &dquo;late-shift&dquo; pa-
tients. Moreover, the distributions in age at onset and
age at shift in our sample were not bimodal. These
distributions suggest that using correlational statistics
rather than group comparisons may be a more valid
way of studying variables, given our current level of
knowledge.
Bondareff and colleagues&dquo; reported on the use-
fulness of age at death in differentiating two sub-
types of AD. Though age at death is determined.with
certainty, its use in clinical studies is limited for ob-
vious reasons. The need for a clinical descriptor that
falls between the onset of the illness and the demise
of the patient is clearly called for in AD research. Age
at shift from questionable to probable AD, according
to the NIH Consensus Criteria, offers a logical refer-
ence point for such a descriptor. Because clinicians use
standardized criteria to determine age at shift, it is
less dependent than age at onset on potential inac-
curacies introduced by informants’ reports. Although
its use is limited to longitudinal clinical studies, it may
assist in refining the characterization and subtyping
of patients with Alzheimer’s disease. 
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